The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Lung Cancer Diagnosis and Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
The global Lung Cancer Diagnosis and Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Diagnosis and Therapeutics in various end use industries. The expanding demands from the Hospitals and Cancer Research Centers, are propelling Lung Cancer Diagnosis and Therapeutics market. Non-Small Cell Lung Cancer, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Small Cell Lung Cancer segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Lung Cancer Diagnosis and Therapeutics market, driven by demand from China, the second largest economy with some signs of stabilising, the Lung Cancer Diagnosis and Therapeutics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Diagnosis and Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Diagnosis and Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Diagnosis and Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Diagnosis and Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Diagnosis and Therapeutics covered in this report include AstraZeneca, Eli Lilly, Sanofi, ArQule, Daiichi Sankyo, Celgene, Merck, Pfizer and Boehringer Ingelheim, etc.
The global Lung Cancer Diagnosis and Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eli Lilly
Sanofi
ArQule
Daiichi Sankyo
Celgene
Merck
Pfizer
Boehringer Ingelheim
Roche
Genentech
GSK
Pharmacyclics
Novartis
Bayer
Bristol-Myers Squibb
Eisai
AbbVie
Global Lung Cancer Diagnosis and Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Diagnosis and Therapeutics market, Segment by Type:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Global Lung Cancer Diagnosis and Therapeutics market, by Application
Hospitals
Cancer Research Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Diagnosis and Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Lung Cancer Diagnosis and Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Diagnosis and Therapeutics in various end use industries. The expanding demands from the Hospitals and Cancer Research Centers, are propelling Lung Cancer Diagnosis and Therapeutics market. Non-Small Cell Lung Cancer, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Small Cell Lung Cancer segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Lung Cancer Diagnosis and Therapeutics market, driven by demand from China, the second largest economy with some signs of stabilising, the Lung Cancer Diagnosis and Therapeutics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Diagnosis and Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Diagnosis and Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Diagnosis and Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Diagnosis and Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Diagnosis and Therapeutics covered in this report include AstraZeneca, Eli Lilly, Sanofi, ArQule, Daiichi Sankyo, Celgene, Merck, Pfizer and Boehringer Ingelheim, etc.
The global Lung Cancer Diagnosis and Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eli Lilly
Sanofi
ArQule
Daiichi Sankyo
Celgene
Merck
Pfizer
Boehringer Ingelheim
Roche
Genentech
GSK
Pharmacyclics
Novartis
Bayer
Bristol-Myers Squibb
Eisai
AbbVie
Global Lung Cancer Diagnosis and Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Diagnosis and Therapeutics market, Segment by Type:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Global Lung Cancer Diagnosis and Therapeutics market, by Application
Hospitals
Cancer Research Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Diagnosis and Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Lung Cancer Diagnosis and Therapeutics
1.1 Lung Cancer Diagnosis and Therapeutics Market Overview
1.1.1 Lung Cancer Diagnosis and Therapeutics Product Scope
1.1.2 Lung Cancer Diagnosis and Therapeutics Market Status and Outlook
1.2 Global Lung Cancer Diagnosis and Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Lung Cancer Diagnosis and Therapeutics Market Size by Region (2018-2029)
1.4 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Lung Cancer Diagnosis and Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Lung Cancer Diagnosis and Therapeutics Market Size (2018-2029)
1.6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size (2018-2029)
1.6.2 Europe Lung Cancer Diagnosis and Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size (2018-2029)
1.6.4 Latin America Lung Cancer Diagnosis and Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size (2018-2029)
2 Lung Cancer Diagnosis and Therapeutics Market by Type
2.1 Introduction
2.1.1 Non-Small Cell Lung Cancer
2.1.2 Small Cell Lung Cancer
2.2 Global Lung Cancer Diagnosis and Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Type (2018-2029)
3 Lung Cancer Diagnosis and Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Cancer Research Centers
3.2 Global Lung Cancer Diagnosis and Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Breakdown by Application (2018-2029)
4 Lung Cancer Diagnosis and Therapeutics Competition Analysis by Players
4.1 Global Lung Cancer Diagnosis and Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lung Cancer Diagnosis and Therapeutics as of 2022)
4.3 Date of Key Players Enter into Lung Cancer Diagnosis and Therapeutics Market
4.4 Global Top Players Lung Cancer Diagnosis and Therapeutics Headquarters and Area Served
4.5 Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Lung Cancer Diagnosis and Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.1.4 AstraZeneca Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.2.4 Eli Lilly Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Sanofi
5.3.1 Sanofi Profile
5.3.2 Sanofi Main Business
5.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.3.4 Sanofi Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 ArQule Recent Developments
5.4 ArQule
5.4.1 ArQule Profile
5.4.2 ArQule Main Business
5.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.4.4 ArQule Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 ArQule Recent Developments
5.5 Daiichi Sankyo
5.5.1 Daiichi Sankyo Profile
5.5.2 Daiichi Sankyo Main Business
5.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.5.4 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Daiichi Sankyo Recent Developments
5.6 Celgene
5.6.1 Celgene Profile
5.6.2 Celgene Main Business
5.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.6.4 Celgene Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Celgene Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.7.4 Merck Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.8.4 Pfizer Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
5.9 Boehringer Ingelheim
5.9.1 Boehringer Ingelheim Profile
5.9.2 Boehringer Ingelheim Main Business
5.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.9.4 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Boehringer Ingelheim Recent Developments
5.10 Roche
5.10.1 Roche Profile
5.10.2 Roche Main Business
5.10.3 Roche Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.10.4 Roche Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Roche Recent Developments
5.11 Genentech
5.11.1 Genentech Profile
5.11.2 Genentech Main Business
5.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.11.4 Genentech Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Genentech Recent Developments
5.12 GSK
5.12.1 GSK Profile
5.12.2 GSK Main Business
5.12.3 GSK Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.12.4 GSK Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 GSK Recent Developments
5.13 Pharmacyclics
5.13.1 Pharmacyclics Profile
5.13.2 Pharmacyclics Main Business
5.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.13.4 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Pharmacyclics Recent Developments
5.14 Novartis
5.14.1 Novartis Profile
5.14.2 Novartis Main Business
5.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.14.4 Novartis Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Novartis Recent Developments
5.15 Bayer
5.15.1 Bayer Profile
5.15.2 Bayer Main Business
5.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.15.4 Bayer Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Bayer Recent Developments
5.16 Bristol-Myers Squibb
5.16.1 Bristol-Myers Squibb Profile
5.16.2 Bristol-Myers Squibb Main Business
5.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.16.4 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.16.5 Bristol-Myers Squibb Recent Developments
5.17 Eisai
5.17.1 Eisai Profile
5.17.2 Eisai Main Business
5.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.17.4 Eisai Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.17.5 Eisai Recent Developments
5.18 AbbVie
5.18.1 AbbVie Profile
5.18.2 AbbVie Main Business
5.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Products, Services and Solutions
5.18.4 AbbVie Lung Cancer Diagnosis and Therapeutics Revenue (US$ Million) & (2018-2023)
5.18.5 AbbVie Recent Developments
6 North America
6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Lung Cancer Diagnosis and Therapeutics Market Dynamics
11.1 Lung Cancer Diagnosis and Therapeutics Industry Trends
11.2 Lung Cancer Diagnosis and Therapeutics Market Drivers
11.3 Lung Cancer Diagnosis and Therapeutics Market Challenges
11.4 Lung Cancer Diagnosis and Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
